Table 4.
Pharmacokinetic parameters of GBD formulations after oral administration
| Pharmacokinetic parameters | GBD–COM | GBD–MCC–NANO | GBD–LAC–NANO |
|---|---|---|---|
|
| |||
| Cmax (µg/mL) | 0.39±0.10 | 2.03±0.06 | 2.21±0.18 |
| Tmax (hours) | 2±0.00 | 1±0.00 | 1±0.00 |
| AUC0–24 h (µg hours/mL) | 4.58±0.62 | 9.05±0.41 | 10.27±0.50 |
| F % | 100.00 | 197.60 | 224.23 |
Abbreviations: AUC0–24 h, area under the plasma concentration–time curve in the first 24 h; COM, commercial formulation; GBD, glyburide; GBD–LAC–NANO, formulation of GBD nanocrystals and lactose; GBD–MCC–NANO, formulation of GBD nanocrystals and microcrystalline cellulose; LAC, lactose monohydrate; MCC, microcrystalline cellulose.